Back to search results

A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Abroad (travel likely)RecruitingPHASE1

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Beijing Gobroad Boren Hospital, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Xiequn Chen, MD, PHD) · 20203009@nwu.edu.cn · (+86)13991832567
    Contact: Study coordinator (Xiequn Chen, MD, PHD)

  • The Affiliated Hospital of Northwest University Xi'an No.3 Hospital, Xi’an, Shanxi, China

    Contact: Study coordinator (Yajin Zhang, MD, PHD) · zhangyj3@gobroadhealthcare.com · (+86)18601333856
    Contact: Study coordinator (Yajin Zhang, MD, PHD)

  • The first affiliated hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

    Contact: Study coordinator (He Huang, MD, PhD) · hehuangyu@126.com · (+86)13605714822
View source on ClinicalTrials.gov(opens in a new tab)